Cytokinetics has begun dosing patients in Japan in a Phase III cardiovascular outcomes clinical trial (GALACTIC-HF) of omecamtiv mecarbil as a potential heart failure treatment.

Currently being developed in collaboration with Amgen, omecamtiv mecarbil is an investigational cardiac myosin activator designed to increase cardiac contractility.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The double-blind, randomised, placebo-controlled multi-centre GALACTIC-HF trial will evaluate the ability of omecamtiv mecarbil and standard-of-care combination to minimise the risk for cardiovascular death or heart failure in patients with high chronic heart failure risk and decreased ejection fraction.

Expected to enrol around 8,000 subjects with symptomatic chronic heart failure at more than 800 centres in 34 countries, the trial is being performed by Amgen in partnership with Cytokinetics.

Dosing of the first patient in Japan triggers a milestone payment of $10m from Amgen.

See Also:

Last month, the firm reported positive results from a Phase II Japanese trial with omecamtiv mecarbil.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Results indicated that the trial met its pharmacokinetic primary endpoint and a secondary endpoint of statistically significant improvement in systolic ejection time (SET)."

The Phase II trial assessed the safety, tolerability, pharmacokinetics and cardiac function effect of omecamtiv mecarbil in patients with chronic heart failure.

Results indicated that the trial met its pharmacokinetic primary endpoint and a secondary endpoint of statistically significant improvement in systolic ejection time (SET).

The trial’s pharmacodynamics, pharmacokinetics, tolerability and safety data was found to be consistent with that of previous trials.

Subject to Cytokinetics’ specified development and commercialisation rights, Amgen holds an exclusive, worldwide licence to omecamtiv mecarbil and related compounds.

Amgen also partnered with French company Servier for exclusive commercialisation rights in Europe and the Commonwealth of Independent States.